echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > A breakthrough in Yangtze River's proprietary Chinese medicines!

    A breakthrough in Yangtze River's proprietary Chinese medicines!

    • Last Update: 2021-11-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 15th, Yangzijiang submitted a clinical application for a new drug for Qingchang Wenzhong Tablets, which is the first class 1 new drug declared by Yangzijiang this year for proprietary Chinese medicines
    .
    The company's clinical application for Sanfengtongqiao dripping pills for category 2.


    3 new drugs submitted in April this year has been approved, and the indication is seasonal allergic rhinitis


    Figure 1: New drugs declared by Yangtze River since 2021

    Source: CDE official website

    Figure 2: Clinical progress of new drugs

    Source: China Drug Clinical Trial Publicity Library of Meinenet

    Since the beginning of this year, Yangtze River has applied for clinical application of 3 new drugs: the indication is analgesic chemical medicine Class 1 new drug YR-1702 injection and the indication is seasonal allergic rhinitis Chinese medicine Class 2.
    3 new drug Sanfeng Tongqiao dripping pills have been approved.
    Approval of clinical trials, of which YR-1702 injection is currently undergoing phase I clinical trials
    .

    Table 1: The generic status of Yangtze River's chemical drugs declared and marketed from 2021 to now

    Source: Meinenet MED2.
    0 Chinese Drug Evaluation Database

    Compared with proprietary Chinese medicines, Yangtze River has worked more deeply in the field of chemical medicines.
    Since 2021, it has submitted 30 applications for the imitation of chemical medicines, including brivaracetam injection, eslicarbazepine acetate tablets, and diquafoso sodium drops Eye drops, gadobutrol injection, lacosamide syrup, oseltamivir phosphate dry syrup, peramivir injection, regorafenib tablets and ticagrelor dispersible tablets are expected to hit the country's first imitation
    .
    In addition, it has also submitted generic clinical applications for obeticholic acid tablets, ranolazine sustained-release tablets, pregabalin sustained-release tablets, etomidate emulsion injection, drafloxacin for injection, and carfilzomib for injection.


    Batch


    Source: CDE official website, Minet database

    The review data statistics are as of October 18, if there are any errors or omissions, please correct me


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.